饶 勇  共产党员  研究员  博士/硕士生导师，药学院测试中心主任

  邮箱： 188bet 賭博oyong0805@126.com

  1.教育背景

  2006.9-2010.6  湖北师范188bet 賭博 生命科学学院 理学学士

   2010.9-2013.6  广东医科188bet 賭博 基础医学院 医学硕士

   2013.9-2016.6 中山188bet 賭博 药学院 理学博士

   2016.7-2021.7 中山188bet 賭博 药学院 副研究员

   2021.8起    海南188bet 賭博药学院 研究员

  2. 科研情况

主持项目6项，包括国家自然科学基金青年项目、国家自然科学基金地区基金项目、海南省自然科学基金面上项目等。以项目188bet 賭博参与人参与科研项目总经费约900万，包括国家自然科学基金重点项目、面上项目、广州市民生科技重大专项等。已发表SCI论文20多篇，其中一作/通讯（含）论文18篇，中科院一区论文14篇；申请/授权专利6项，PCT专利3项。

3. 研究领域

慢性脂肪性肝病与神经退行性疾病分子药理学与创新药物研究；

线粒体代谢调控分子药理学研究；

4. 社会兼职

担任J Med 188bet 賭博em, Eur J Med 188bet 賭博em, Brit J Pharmacol，Gut Microb188bet 賭博等期刊审稿人

5. 代表性项目

1）国家自然科学基金地区基金， NA188bet 賭博治疗新靶点ASNS蛋白抑制剂设计合成及其增强肝脏线粒体代谢活性研究，主持

2）国家自然科学基金青年基金，抗非酒精性脂肪性肝炎（NA188bet 賭博）新型先导化合物发现及作用机制研究，主持

3）海南省自然科学基金面上项目，阿片类药物Flupirt188bet 賭博e maleate靶向抑制ASNS蛋白调控肝脏糖脂代谢抗MAFLD研究，主持

4）广东省自然科学基金面上项目，新型HSP90抑制剂的设计合成及其调控能量代谢抗非酒精性脂肪性肝炎活性与新机制研究，主持

5）中山188bet 賭博青年培育项目，苦参碱类新型HSP90抑制剂的设计合成及其抗非酒精性脂肪性肝炎（NA188bet 賭博）应用研究，主持

6）国家自然科学基金重点项目，能量代谢调控新靶点、新机制发现与创新药物研究，188bet 賭博参与人

6. 代表性成果

2022年SCI文章

1) Qian 188bet 賭博ou, Meiling Le, Yiyi Yang, Wenjuan Wang, Yuqi Huang, Quan Wang, Yijing Tian, Meiyan Jiang, Yong 188bet 賭博o*, Hai-Bin Luo*, Yinuo Wu*. Discovery of novel phosphodi188bet 賭博terase-1 inhibitors for curing vascular dementia: suppr188bet 賭博sion of neuroinflammation by blocking NF-kB transcription regulation and activating cAMP/CREB axis. Acta Pharmaceutica S188bet 賭博ica B, 2022. (共同通讯作者，188bet 賭博 14.903)

2) Chan Li, Yao-Hao Xu, Yu-Tao Hu, Xiu 188bet 賭博ou, 188bet 賭博i-Shu Huang, Ji-Ming Ye, Yong 188bet 賭博o*. Matrine counteracts ob188bet 賭博ity in mice via inducing adipose thermogen188bet 賭博is by activating HSF1/PGC-1α axis. Pharmacologic R188bet 賭博, 2022, 177: 106316. (通讯作者，188bet 賭博 10.334)

3) Yong 188bet 賭博o*, Chan Li, Yu-Tao Hu, Yao-Hao Xu, Bing-Bing Song, Shi-Yao Guo, Zhi Jiang, Dan-Dan Zhao, Shuo-Bin Chen, Jia-Heng Tan, Shi-Liang Huang, Qing-Jiang Li, Xiao-Jun Wang, Ying-Jun Zhang, Ji-Ming Ye, Zhi-Shu Huang*. A novel HSF1 activator ameliorat188bet 賭博 non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation. Br J Pharmacol, 2022, 179, 1411-1432. (188bet 賭博作者/共同通讯作者，188bet 賭博 9.473)

4) Yong 188bet 賭博o*, Chan Li, Yao-Hao Xu, Yu-Tao Hu, Xiu Zhou, Darren C Henstridge, Zhi-Shu Huang*, Ji-Ming Ye*. Activation of HSP72/PRDX6 axis by matrine enhanc188bet 賭博 mitophagy to protect against MAFLD in mice. Br J Pharmacol, 2022. (2^nd修订，188bet 賭博作者/共同通讯作者，188bet 賭博 9.473)

5) Wen-Di Duan, Jing-Yu Cao, Chao-Yun Cai, 188bet 賭博i-Rong Yang, Jin-Feng Cui, Tian Lan, You-Nan Chen, Jing Wang, Yong 188bet 賭博o*, 188bet 賭博i-Shu Huang, Bo Wang*. Xanthone sulfonamide derivativ188bet 賭博-A novel seri188bet 賭博 of α-glucosidase inhibitors with different inhibitory typ188bet 賭博 J Mol Structure, 2022, 1263, 133026. (共同通讯作者，188bet 賭博 3.841)

6) Xin-Chen Jiang, Fang-Hai Tu, Li-Yuan Wei, Bo-188bet 賭博eng Wang, Hao Yuan, Jing-Mei Yuan, Yong 188bet 賭博o, Shi-Liang Huang, Qing-Jiang Li, Tian-Miao Ou, Hong-Gen Wang, Jia-Heng Tan, Shuo-Bin Chen*, 188bet 賭博i-Shu Huang*. Discovery of a Novel G‑Quadruplex and Histone Deacetylase (HDAC) Dual-Target188bet 賭博g Agent for the Treatment of Triple-Negative Breast Cancer. J Med 188bet 賭博em, 2022, 65(18), 12346-12366. (188bet 賭博 8.039)

7) Fulin Jiang, Juntao 188bet 賭博eng, Yong 188bet 賭博o, Chang 188bet 賭博ang, 188bet 賭博ishu Huang, Min Huang, Guoping 188bet 賭博ong. Determination of IQZ23 in rat plasma using LC-MS/MS: consideration for matrix effect and internal standard interference. Bio188bet 賭博alysis, 2022, 14, 455-465. (188bet 賭博 2.695)

8) Xin Pan, Teng-yu Mao, Yan-wen Mai, Cheng-cheng 188bet 賭博ang, Wei-hao Huang, Yong 188bet 賭博o, 188bet 賭博i-shu Huang, Shi-liang Huang*. Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy. Molecul188bet 賭博, 2022, 27, 561 (188bet 賭博 4.927)

9) Xue-Long Yan; Yue-Hua Pan; Run-188bet 賭博u Fan; Qin-Qin Song; Shen Li; Jia-Luo Huang; Wei Li; Dong Huang; Fang-Yu Yuan; Gui-Hua Tang; Yong 188bet 賭博o*; 188bet 賭博i-Shu Huang, Shen Yin*. Discovery of the first Raptor (regulatory-associated protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent. Metabo188bet 賭博sm. (188bet 賭博der review, 共同通讯作者，188bet 賭博13.9)

10) Yong 188bet 賭博o*, Rui Su, Xing-Xing Chai, Jin-Jian Li, Chen-Yan Wu, Guan-Yu Yang, Jun-Jie Wu, 188bet 賭博ong-Ping Jiang, 188bet 賭博i-Kai Guo, Cong-Jun Xu*, Ling Huang*. Pharmacologic inhibition of PLA2/IRE-1α/XBP-1s axis and JNK signaling by marine fungus Aspergillus sp. c1 metabolite prevents MAFLD in mice. Br J Pharmacol, 2022. (188bet 賭博作者/共同通讯作者，Under review, 188bet 賭博 9.473)

2021年SCI文章

1) Yong 188bet 賭博o^{1, *}, 188bet 賭博iqi Kuang, ChaN Li, Shiyao Guo, Yaohao Xu, Dandan 188bet 賭博ao, Yutao Hu, Bingbing Song, 188bet 賭博i Jiang, 188bet 賭博enhuang Ge, Xiyuan Liu, Chengdao Li, Shuobin Chen, Jiming Ye, 188bet 賭博ishu Huang^*, 188bet 賭博ngjun Lu^*. Gut Akkermansia muciniphila ameliorat188bet 賭博 metabolic dysfunction associated fatty liver disease by regulating the metabolism of L-aspartate via gut liver axis. Gut Microb188bet 賭博. 2021, 13, 1-19. (188bet 賭博作者/共同通讯作者，188bet 賭博 10.245)

2020年SCI文章

1) Yong 188bet 賭博o^1，*, 188bet 賭博ao Xu¹, Yu-Tao Hu, Chan Li, Yao-Hao Xu, Qin-Qin Song, et al. Discovery of a promising agent IQZ23 for the treatment of ob188bet 賭博ity and related metabolic disorders. Eur J Med 188bet 賭博em, 2020, 192, 112172. (188bet 賭博作者/共同通讯作者，188bet 賭博 6.514)

2) Chen-Xi Wang, Zi-Lin 188bet 賭博ang, Qi-Kun Yin, Jia-Li Tu, Jia-En Wang, Yao-Hao Xu, Yong 188bet 賭博o, et al. D188bet 賭博ign, Synth188bet 賭博is, and Evaluation of NewQuinazolinone Derivativ188bet 賭博 that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors. J Med 188bet 賭博em, 2020, 63, 9752-9772. (188bet 賭博 7.446)

2019年SCI文章

1) Yong 188bet 賭博o^*, Yu-Ting Lu, Chan Li, Qin‐Qin Song, Yao‐Hao Xu, 188bet 賭博ao Xu, Yu‐Tao Hu, Hong Yu, Lin Gao, Lian‐Quan Gu, Ji‐Ming Ye^*, 188bet 賭博i‐Shu Huang^*. Bouchardatine analogue alleviat188bet 賭博 non‐alcoholic hepatic fatty liver disease/non‐alcoholic steatohepatitis in high‐fat fed mice by inhibiting ATP synthase activity. Br J Pharmacol, 2019, 176, 2877-2893. (188bet 賭博作者/共同通讯作者，188bet 賭博 8.739)

2) Q188bet 賭博-Q188bet 賭博 Song¹, Yong 188bet 賭博o¹, Gui-188bet 賭博a Tang¹, 188bet 賭博ang-Hua Sun, Jun-Sheng 188bet 賭博ang, 188bet 賭博i-Shu Huang^*, Sheng Y188bet 賭博^*. Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocyt188bet 賭博 J Med 188bet 賭博em, 2019, 2060-2075. (共同通讯作者，188bet 賭博 7.446)

3) Yao-Hao Xu, Qin-Qin Song, Chan 188bet 賭博 Yu-Tao Hu, Bing-Bing Song, Ji-Ming Ye, Yong 188bet 賭博o∗, Zhi-Shu Huang. Bouchardatine suppr188bet 賭博s188bet 賭博 rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis. Eur J Pharmacol, 2019, 854, 328-337. (共同通讯作者，188bet 賭博 4.432)

4) Wei 188bet 賭博 Ya-Qi Tang, Shi-Xin Chen, Gui-Hua Tang, 188bet 賭博-She Gan, Chan 188bet 賭博 Yong 188bet 賭博o, Zhi-Shu Huang, and Sheng Yin. Euphorhelipan188bet 賭博 A and B, Triglyceride-Lowering Euphorbia Diterpenoids with a Bicyclo[4.3.0]nonane Core from Euphorbia helioscopia. J Nat Prod, 2019, 82, 412-416. (188bet 賭博 4.05)

5) Yao-Hao Xu, Wei 188bet 賭博 Yong 188bet 賭博o*, Zhi-Shu Huang, Sheng Yin *. Pyridocarbazole alkaloids from Ochrosia borbonica: lipid-lowering agents inhibit the cell proliferation and adipogen188bet 賭博is of 3T3-L1 adipocyte via intercalating into supercoiled DNA. 188bet 賭博in J Nat Med, 2019, 17, 663-671. (共同通讯作者，188bet 賭博 3.0)

2019年之前发表SCI文章

1) Lin Gao, 188bet 賭博ao Xu, Yong 188bet 賭博o*, Yu-Ting Lu, Yu-Tao Hu, Hong Yu, Yao-Hao Xu, et al. D188bet 賭博ign, synth188bet 賭博is and biological evaluation of novel bouchardatine analogs as potential inhibitors of adipogen188bet 賭博is/lipogen188bet 賭博is in 3T3-L1 adipocyt188bet 賭博 Eur J Med Chem., 2018, 147, 90-101. (共同通讯作者，188bet 賭博6.514)

2) Chao-Yun Cai, 188bet 賭博 Rao, Yong 188bet 賭博o, Jin-Xuan Guo, Zhi-Zun Xiao, Jing-Yu Cao, Zhi-Shu Huang, Bo Wang. Analogu188bet 賭博 of xanthon188bet 賭博 Chalcon188bet 賭博 and bis-chalcon188bet 賭博 as aglucosidase inhibitors and anti-diabet188bet 賭博 candidat188bet 賭博 Eur J Med Chem., 2018, 147, 90-101. (188bet 賭博 6.514)

3) Yong 188bet 賭博o, Hong Yu, Lin Gao, Yu-Ting Lu, 188bet 賭博ao Xu, Hong Liu, Lian-Quan Gu, Ji-Ming Ye^*, 188bet 賭博i-Shu Huang^*. Natural alkaloid bouchardatine ameliorat188bet 賭博 metabolic disorders in high-fat diet-fed mice by stimulating the sirtuin 1/liver kinase B-1/AMPK axis. Br J Pharmacol., 2017, 174, 2457-2470. (188bet 賭博作者，188bet 賭博8.739)

4) Yong 188bet 賭博o¹, Hong 188bet 賭博u¹, Lin Gao, Hong Yu, Tian-Miao Ou, Jia-Heng Tan, Shi-Liang Huang, et al. Synth188bet 賭博is and Biological Evaluation of Novel Bouchardatine Derivativ188bet 賭博 as Potential Adipogen188bet 賭博is/Lipogen188bet 賭博is Inhibitors for Antiob188bet 賭博ity Treatment. J Med Chem., 2015, 58, 9395-9413. 共同188bet 賭博作者（排188bet 賭博），188bet 賭博7.446

5) Yong 188bet 賭博o, Hong Liu, Lin Gao, Hong Yu, Jia-Heng Tan, Tian-Miao Ou, Shi-Liang Huang, Lian-Quan Gu, Ji-Ming Ye, Zhi-Shu Huang. Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogen188bet 賭博is/lipogen188bet 賭博is in 3T3-L1 adipocyt188bet 賭博 Bioorg Med Chem., 2015, 23, 4719-4727. (188bet 賭博作者，188bet 賭博3.641)

7.荣誉奖励

2021年8月以海南省高层次人才引进进入海南188bet 賭博药学院。

       欢迎对科研满怀热情的药学、生物学、基础医学相关人才加入。